Home » Stocks » Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (MDGL)

Stock Price: $102.75 USD 0.14 (0.13%)
Updated Aug 3, 2020 10:55 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.59B
Revenue (ttm) n/a
Net Income (ttm) -105.00M
Shares Out 15.43M
EPS (ttm) -6.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $102.75
Previous Close $102.61
Change ($) 0.14
Change (%) 0.13%
Day's Open 103.81
Day's Range 101.93 - 104.46
Day's Volume 8,288
52-Week Range 56.82 - 127.25

More Stats

Market Cap 1.59B
Enterprise Value 1.18B
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 15.43M
Float 5.77M
EPS (basic) -6.81
EPS (diluted) -6.81
FCF / Share -4.28
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.94M
Short Ratio 19.59
Short % of Float 35.51%
Beta 1.76
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.13
Revenue n/a
Operating Income -114.86M
Net Income -105.00M
Free Cash Flow -66.10M
Net Cash 407.91M
Net Cash / Share 26.44
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -16.11%
ROE -24.59%
ROIC -29.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 12
Overweight 0
Hold 3
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$170.36*
(65.81% upside)
Low
104
Current: $102.75
High
230
Target: 170.36
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-------0.157.5814.80
Revenue Growth--------98.06%-48.77%-
Gross Profit-------0.157.5814.80
Operating Income-94.97-40.68-32.06-25.22-3.23-83.95-87.56-60.94-45.43-36.90
Net Income-83.95-32.81-31.15-26.39-6.84-86.16-90.19-62.79-47.38-37.47
Shares Outstanding15.3914.8012.245.200.172.812.031.701.351.15
Earnings Per Share-5.45-2.22-2.54-5.07-40.03-30.45-44.45-37.10-35.00-32.55
Operating Cash Flow-41.62-25.51-22.32-17.61-3.14-78.93-77.41-54.14-47.30-38.20
Capital Expenditures-0.17-0.02-0.130.70--0.14-0.77-0.51-0.69-0.14
Free Cash Flow-41.80-25.53-22.44-16.91-3.14-79.07-78.18-54.64-47.99-38.34
Cash & Equivalents43948419240.500.3197.6991.4810139.7350.97
Total Debt0.68---48.6013.9123.4012.4016.6515.23
Net Cash / Debt43848419240.50-48.2983.7868.0888.2023.0835.75
Assets44248519241.210.3610195.2010342.3254.07
Liabilities25.498.4410.054.8049.2835.5446.1127.9527.5530.59
Book Value41747718236.41-48.9165.1449.0975.0714.7723.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Madrigal Pharmaceuticals, Inc.
Country United States
Employees 29
CEO Paul A. Friedman

Stock Information

Ticker Symbol MDGL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MDGL

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.